富国银行看好这只生物科技股，牛市情况下将上涨75%

金融界12-04

富国银行认为，Kymera Therapeutics（KYMR）成功的一款实验性治疗药物可能为该公司股票带来更多上涨空间。分析师Derek Archila将Kymera股票评级从“持平”上调至“增持”，并将目标价提高19美元至57美元，这意味着较上周五收盘价有超过21%的上涨空间。今年以来，该股表现已显著跑赢大盘，累计上涨近90%。Archila特别提到Kymera开发的一款针对多种免疫炎症性疾病...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2488181963?lang=zh_CN&edition=full","thumbnail":"http://imgcloud.jrjimg.cn/2024/12/weixin/one_20241204105722849.png","is_english":false,"pubTime":"2024-12-04 10:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488181963","market":"hk","top_or_hot":-1,"title":"富国银行看好这只生物科技股，牛市情况下将上涨75%","media":"金融界","content":"<div>\n<p>富国银行认为，Kymera Therapeutics（KYMR）成功的一款实验性治疗药物可能为该公司股票带来更多上涨空间。分析师Derek Archila将Kymera股票评级从“持平”上调至“增持”，并将目标价提高19美元至57美元，这意味着较上周五收盘价有超过21%的上涨空间。今年以来，该股表现已显著跑赢大盘，累计上涨近90%。Archila特别提到Kymera开发的一款针对多种免疫炎症性疾病...</p>\n\n<a href=\"https://usstock.jrj.com.cn/2024/12/04105745989379.shtml\">网页链接</a>\n\n</div>\n","source":"jinrongjie_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>富国银行看好这只生物科技股，牛市情况下将上涨75%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n富国银行看好这只生物科技股，牛市情况下将上涨75%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-04 10:57 北京时间&nbsp;&nbsp;&nbsp;<a href=https://usstock.jrj.com.cn/2024/12/04105745989379.shtml><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>富国银行认为，Kymera Therapeutics（KYMR）成功的一款实验性治疗药物可能为该公司股票带来更多上涨空间。分析师Derek Archila将Kymera股票评级从“持平”上调至“增持”，并将目标价提高19美元至57美元，这意味着较上周五收盘价有超过21%的上涨空间。今年以来，该股表现已显著跑赢大盘，累计上涨近90%。Archila特别提到Kymera开发的一款针对多种免疫炎症性疾病...</p>\n\n<a href=\"https://usstock.jrj.com.cn/2024/12/04105745989379.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0683600562.USD","symbol_name":"AB SELECT US EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://usstock.jrj.com.cn/2024/12/04105745989379.shtml","article_id":"2488181963","we_media_id":null,"thumbnails":["http://imgcloud.jrjimg.cn/2024/12/weixin/one_20241204105722849.png"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488181963","pubTimestamp":1733281027,"columns":[],"sourceInfo":{"source_id":"jinrongjie_highlight","name":"金融界"},"weMediaInfo":null,"summary":"富国银行认为，Kymera Therapeutics成功的一款实验性治疗药物可能为该公司股票带来更多上涨空间。今年以来，该股表现已显著跑赢大盘，累计上涨近90%。预计该药物的I期试验数据将在2025年上半年公布。他预测数据可能显示出“良好”的安全性特征，并认为牛市情况下股价可能上涨75%。目前，Kymera的平均目标价为57.88美元，较当前股价有超过20%的上涨空间。受评级上调推动，该公司股价在周一交易时段上涨逾2%。","collect":0,"end_time":0,"defaultTopTitle":"jrj.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159837":"生物科技","LU0683600562.USD":"AB SELECT US EQUITY \"A\" (USD) ACC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","BK4504":"桥水持仓","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0787776722.HKD":"AB SELECT US EQUITY PORTFOLIO \"A\" (HKD) ACC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0971096721.USD":"富达环球金融服务 A","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","LU0149725797.USD":"汇丰美国股市经济规模基金","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1069347547.HKD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (HKD) INC","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","WFC":"富国银行","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4585":"ETF&股票定投概念","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0048573561.USD":"FIDELITY AMERICA \"A\" (USD) INC","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU1791807156.HKD":"BGF WORLD FINANCIALS \"A2\" (HKDHDG) ACC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","BK4559":"巴菲特持仓","BK4501":"段永平概念","LU0289960550.SGD":"AB FCP I - GLOBAL EQUITY BLEND PORTFOLIO 'A' (SGD) ACC","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","BK4588":"碎股","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","LU0251142724.SGD":"Fidelity America A-SGD","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","BK4207":"综合性银行","LU0106831901.USD":"贝莱德世界金融基金A2","LU0175139822.USD":"AB FCP I Global Equity Blend A USD","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H"},"translate_title":"Wells Fargo Is Bullish On This Biotech Stock That Will Gain 75% In Bull Scenario","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159837":1,"WFC":1},"content_text":"富国银行认为，Kymera Therapeutics（KYMR）成功的一款实验性治疗药物可能为该公司股票带来更多上涨空间。分析师Derek Archila将Kymera股票评级从“持平”上调至“增持”，并将目标价提高19美元至57美元，这意味着较上周五收盘价有超过21%的上涨空间。今年以来，该股表现已显著跑赢大盘，累计上涨近90%。Archila特别提到Kymera开发的一款针对多种免疫炎症性疾病的口服治疗药物KT-621。预计该药物的I期试验数据将在2025年上半年公布。他预测数据可能显示出“良好”的安全性特征，并认为牛市情况下股价可能上涨75%。“我们认为KT-621的I期数据将是一个重要的去风险事件，而市场对该项目的估值仍相对保守，尤其考虑到其潜在的大规模终端市场，”Archila在周一的客户报告中表示。“如果KT-621能展现出类似‘口服杜匹特（dupilumab）’的特性，我们估计该药物可能成为一款适用于多种适应症的数十亿美元级别的产品。”基于这一观点，这位分析师认为KT-621为公司销售增长提供了“巨大的”机会，尤其是考虑到目前杜匹特（Dupixent）注射剂的成功。他指出，Dupixent在过去12个月的销售额约为136亿美元。“我们认为，KT-621具有推动市场扩展的潜力，尤其是口服疗法开具处方更为便利。如果其疗效和安全性数据在特应性皮炎、哮喘及慢性阻塞性肺疾病等适应症中与Dupixent相当（且这只是个开始），其收入潜力可能甚至超过Dupixent，”Archila补充道。据LSEG数据显示，华尔街对这家生物制药公司整体持乐观态度。在覆盖Kymera的18位分析师中，有14位给予了强力买入或买入评级，其余4位则为持有评级。目前，Kymera的平均目标价为57.88美元，较当前股价有超过20%的上涨空间。受评级上调推动，该公司股价在周一交易时段上涨逾2%。\n\n\r\n            责任编辑：栎树","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2488181963"}